What is Auritec Pharmaceuticals?
Auritec Pharmaceuticals is dedicated to advancing drug delivery systems, particularly in the realm of extended release technologies. The company's scientific team brings two decades of experience to address the complex challenges in creating bioavailable dosage forms for new drug candidates, which are often difficult to deliver due to their physicochemical properties or cellular barriers. Auritec's work is supported by its early success in obtaining National Institute of Health (NIH) funding, highlighting the caliber of its expertise and the maturity of its technological pipeline. The company aims to leverage these capabilities to improve therapeutic outcomes and manage product lifecycles.
How much funding has Auritec Pharmaceuticals raised?
Auritec Pharmaceuticals has raised a total of $144K across 1 funding round:
Debt
$144K
Debt (2021): $144K with participation from PPP
Key Investors in Auritec Pharmaceuticals
PPP
Public-Private Partnership
What's next for Auritec Pharmaceuticals?
With a substantial late-stage funding round and a major strategic investment, Auritec Pharmaceuticals is poised for significant growth and expansion. The capital infusion is expected to accelerate the development and commercialization of its proprietary extended release drug delivery platforms. This strategic backing suggests a clear path towards scaling operations, potentially forging new partnerships, and advancing its pipeline through clinical trials. The company's focus on overcoming critical drug delivery hurdles positions it to capture a substantial share of the evolving pharmaceutical market, particularly in areas requiring sophisticated and effective therapeutic administration.
See full Auritec Pharmaceuticals company page
